Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Common Equity (2018 - 2025)

TELA Bio has reported Common Equity over the past 8 years, most recently at $6.3 million for Q4 2025.

  • Quarterly results put Common Equity at $6.3 million for Q4 2025, down 77.82% from a year ago — trailing twelve months through Dec 2025 was $6.3 million (down 77.82% YoY), and the annual figure for FY2025 was $6.3 million, down 77.82%.
  • Common Equity for Q4 2025 was $6.3 million at TELA Bio, up from $1.6 million in the prior quarter.
  • Over the last five years, Common Equity for TELA hit a ceiling of $41.7 million in Q1 2021 and a floor of -$6.3 million in Q3 2024.
  • Median Common Equity over the past 5 years was $16.3 million (2024), compared with a mean of $16.9 million.
  • Biggest five-year swings in Common Equity: skyrocketed 2694.36% in 2023 and later crashed 120.53% in 2024.
  • TELA Bio's Common Equity stood at $20.1 million in 2021, then fell by 28.82% to $14.3 million in 2022, then skyrocketed by 31.99% to $18.9 million in 2023, then surged by 50.72% to $28.5 million in 2024, then plummeted by 77.82% to $6.3 million in 2025.
  • The last three reported values for Common Equity were $6.3 million (Q4 2025), $1.6 million (Q3 2025), and $9.2 million (Q2 2025) per Business Quant data.